Amphastar Pharma Financials
This page shows Amphastar Pharma (AMPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Amphastar Pharma has an operating margin of 28.1%, meaning the company retains $28 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is down from 30.6% the prior year.
Amphastar Pharma's revenue grew 13.6% year-over-year to $732.0M, a solid pace of expansion. This earns a growth score of 67/100.
Amphastar Pharma carries a low D/E ratio of 0.84, meaning only $0.84 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 80/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.07, Amphastar Pharma holds $3.07 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Amphastar Pharma converts 23.5% of revenue into free cash flow ($172.3M). This strong cash generation earns a score of 100/100.
Amphastar Pharma earns a strong 21.8% return on equity (ROE), meaning it generates $22 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 87/100. This is up from 21.5% the prior year.
Amphastar Pharma scores 2.60, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Amphastar Pharma passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Amphastar Pharma generates $1.34 in operating cash flow ($213.4M OCF vs $159.5M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Amphastar Pharma earns $6.8 in operating income for every $1 of interest expense ($205.4M vs $30.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Amphastar Pharma generated $732.0M in revenue in fiscal year 2024. This represents an increase of 13.6% from the prior year.
Amphastar Pharma's EBITDA was $258.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.1% from the prior year.
Amphastar Pharma generated $172.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 18.6% from the prior year.
Amphastar Pharma reported $159.5M in net income in fiscal year 2024. This represents an increase of 16.0% from the prior year.
Amphastar Pharma earned $3.06 per diluted share (EPS) in fiscal year 2024. This represents an increase of 17.7% from the prior year.
Amphastar Pharma held $151.6M in cash against $613.5M in long-term debt as of fiscal year 2024.
Amphastar Pharma had 48M shares outstanding in fiscal year 2024. This represents a decrease of 0.9% from the prior year.
Amphastar Pharma's gross margin was 51.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 3.4 percentage points from the prior year.
Amphastar Pharma's operating margin was 28.1% in fiscal year 2024, reflecting core business profitability. This is down 2.5 percentage points from the prior year.
Amphastar Pharma's net profit margin was 21.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 0.5 percentage points from the prior year.
Amphastar Pharma's ROE was 21.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 0.3 percentage points from the prior year.
Amphastar Pharma invested $73.9M in research and development in fiscal year 2024. This represents an increase of 0.2% from the prior year.
Amphastar Pharma spent $85.5M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents an increase of 47.0% from the prior year.
Amphastar Pharma invested $41.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 7.5% from the prior year.
AMPH Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $191.8M+10.0% | $174.4M+2.3% | $170.5M-8.6% | $186.5M-2.5% | $191.2M+4.8% | $182.4M+6.1% | $171.8M-3.5% | $178.1M |
| Cost of Revenue | $93.2M+6.0% | $87.9M+3.1% | $85.3M-14.6% | $99.9M+11.9% | $89.3M+2.3% | $87.2M+6.7% | $81.7M-0.3% | $82.0M |
| Gross Profit | $98.6M+14.1% | $86.5M+1.5% | $85.3M-1.6% | $86.6M-15.0% | $101.9M+7.1% | $95.2M+5.6% | $90.1M-6.3% | $96.1M |
| R&D Expenses | $22.4M+11.3% | $20.1M-0.1% | $20.1M+10.8% | $18.1M-13.9% | $21.1M+19.4% | $17.7M+3.6% | $17.0M-16.5% | $20.4M |
| SG&A Expenses | $39.5M+182.1% | $14.0M-12.5% | $16.0M+23.6% | $12.9M-12.7% | $14.8M+11.6% | $13.3M-15.3% | $15.7M+19.5% | $13.1M |
| Operating Income | $25.3M-40.0% | $42.2M+13.1% | $37.3M-17.4% | $45.1M-20.9% | $57.0M+3.3% | $55.2M+15.0% | $48.0M-11.1% | $54.0M |
| Interest Expense | $6.3M0.0% | $6.3M-0.1% | $6.3M-2.2% | $6.4M-4.1% | $6.7M-22.2% | $8.6M0.0% | $8.6M-8.9% | $9.5M |
| Income Tax | $4.2M-49.9% | $8.3M+48.9% | $5.6M-7.0% | $6.0M-17.3% | $7.3M-41.0% | $12.3M+198.0% | $4.1M-11.7% | $4.7M |
| Net Income | $17.4M-44.1% | $31.0M+22.7% | $25.3M-33.4% | $38.0M-6.1% | $40.4M+6.5% | $37.9M-12.1% | $43.2M+19.4% | $36.2M |
| EPS (Diluted) | $0.37-42.2% | $0.64+25.5% | $0.51-31.1% | $0.74-5.1% | $0.78+6.8% | $0.73-9.9% | $0.81+15.7% | $0.70 |
AMPH Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.7B+3.2% | $1.6B-0.7% | $1.6B+3.1% | $1.6B+2.1% | $1.5B+3.6% | $1.5B-5.3% | $1.6B+4.1% | $1.5B |
| Current Assets | $639.5M+10.1% | $580.8M-1.2% | $588.0M+10.1% | $534.1M-2.2% | $545.9M+13.1% | $482.6M-13.0% | $555.1M+13.4% | $489.6M |
| Cash & Equivalents | $216.3M+15.2% | $187.7M+2.7% | $182.8M+20.6% | $151.6M-21.1% | $192.1M+1.3% | $189.6M-5.7% | $201.1M+39.4% | $144.3M |
| Inventory | $185.9M-3.0% | $191.7M+3.4% | $185.5M+20.6% | $153.7M+18.0% | $130.3M+6.5% | $122.4M+6.0% | $115.5M+9.1% | $105.8M |
| Accounts Receivable | $146.8M+10.4% | $133.0M-8.1% | $144.6M+6.1% | $136.3M-2.4% | $139.6M+6.3% | $131.4M-4.9% | $138.1M+20.2% | $114.9M |
| Goodwill | $3.4M+0.2% | $3.4M+7.6% | $3.2M+3.5% | $3.0M-6.4% | $3.3M+4.1% | $3.1M-0.7% | $3.2M-2.0% | $3.2M |
| Total Liabilities | $889.5M+3.7% | $857.9M-2.0% | $875.0M+3.5% | $845.2M+3.4% | $817.5M+5.1% | $778.2M-13.7% | $902.0M+3.3% | $873.5M |
| Current Liabilities | $205.2M+16.3% | $176.4M-11.4% | $199.1M+14.6% | $173.8M+9.3% | $159.0M+16.1% | $137.0M-46.3% | $255.2M+13.2% | $225.4M |
| Long-Term Debt | $608.6M+0.1% | $607.7M+0.6% | $603.9M-1.6% | $613.5M+2.9% | $596.4M+1.6% | $586.9M-1.2% | $594.0M-1.5% | $603.2M |
| Total Equity | $776.7M+2.5% | $757.5M+0.8% | $751.3M+2.6% | $732.3M+0.6% | $727.7M+2.0% | $713.3M+6.1% | $672.4M+5.2% | $639.4M |
| Retained Earnings | $642.5M+2.8% | $625.1M+5.2% | $594.1M+4.4% | $568.8M+7.2% | $530.8M+8.2% | $490.4M+8.4% | $452.4M+10.5% | $409.3M |
AMPH Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $52.6M+47.7% | $35.6M+1.5% | $35.1M+20.9% | $29.0M-51.6% | $60.0M-13.2% | $69.1M+25.0% | $55.3M+131.7% | $23.9M |
| Capital Expenditures | $5.3M-49.4% | $10.6M-1.2% | $10.7M-13.8% | $12.4M-10.0% | $13.8M+128.2% | $6.0M-31.3% | $8.8M-6.9% | $9.4M |
| Free Cash Flow | $47.2M+88.7% | $25.0M+2.7% | $24.4M+46.8% | $16.6M-64.0% | $46.2M-26.8% | $63.1M+35.6% | $46.5M+222.4% | $14.4M |
| Investing Cash Flow | -$19.6M-3039.0% | -$625K-106.0% | $10.5M+129.4% | -$35.7M-3.2% | -$34.6M+50.5% | -$69.9M-558.8% | $15.2M+114.8% | -$103.0M |
| Financing Cash Flow | -$4.3M+85.6% | -$30.2M-108.2% | -$14.5M+57.1% | -$33.8M-48.3% | -$22.8M-112.9% | -$10.7M+21.1% | -$13.6M+71.2% | -$47.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $4.8M-87.6% | $39.2M+256.5% | $11.0M-73.8% | $42.0M+20.1% | $35.0M+3158.0% | $1.1M-64.4% | $3.0M | $0 |
AMPH Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.4%+1.8pp | 49.6%-0.4pp | 50.0%+3.5pp | 46.5%-6.9pp | 53.3%+1.1pp | 52.2%-0.2pp | 52.4%-1.5pp | 54.0% |
| Operating Margin | 13.2%-11.0pp | 24.2%+2.3pp | 21.9%-2.3pp | 24.2%-5.6pp | 29.8%-0.4pp | 30.3%+2.3pp | 27.9%-2.4pp | 30.3% |
| Net Margin | 9.0%-8.8pp | 17.8%+3.0pp | 14.8%-5.5pp | 20.3%-0.8pp | 21.1%+0.3pp | 20.8%-4.3pp | 25.1%+4.8pp | 20.3% |
| Return on Equity | 2.2%-1.9pp | 4.1%+0.7pp | 3.4%-1.8pp | 5.2%-0.4pp | 5.6%+0.2pp | 5.3%-1.1pp | 6.4%+0.8pp | 5.7% |
| Return on Assets | 1.0%-0.9pp | 1.9%+0.4pp | 1.6%-0.9pp | 2.4%-0.2pp | 2.6%+0.1pp | 2.5%-0.2pp | 2.7%+0.3pp | 2.4% |
| Current Ratio | 3.12-0.2 | 3.29+0.3 | 2.95-0.1 | 3.07-0.4 | 3.43-0.1 | 3.52+1.3 | 2.180.0 | 2.17 |
| Debt-to-Equity | 0.78-0.0 | 0.800.0 | 0.80-0.0 | 0.84+0.0 | 0.820.0 | 0.82-0.1 | 0.88-0.1 | 0.94 |
| FCF Margin | 24.6%+10.3pp | 14.3%+0.1pp | 14.3%+5.4pp | 8.9%-15.2pp | 24.1%-10.4pp | 34.6%+7.5pp | 27.1%+19.0pp | 8.1% |
Similar Companies
Frequently Asked Questions
What is Amphastar Pharma's annual revenue?
Amphastar Pharma (AMPH) reported $732.0M in total revenue for fiscal year 2024. This represents a 13.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Amphastar Pharma's revenue growing?
Amphastar Pharma (AMPH) revenue grew by 13.6% year-over-year, from $644.4M to $732.0M in fiscal year 2024.
Is Amphastar Pharma profitable?
Yes, Amphastar Pharma (AMPH) reported a net income of $159.5M in fiscal year 2024, with a net profit margin of 21.8%.
What is Amphastar Pharma's earnings per share (EPS)?
Amphastar Pharma (AMPH) reported diluted earnings per share of $3.06 for fiscal year 2024. This represents a 17.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Amphastar Pharma's EBITDA?
Amphastar Pharma (AMPH) had EBITDA of $258.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Amphastar Pharma have?
As of fiscal year 2024, Amphastar Pharma (AMPH) had $151.6M in cash and equivalents against $613.5M in long-term debt.
What is Amphastar Pharma's gross margin?
Amphastar Pharma (AMPH) had a gross margin of 51.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Amphastar Pharma's operating margin?
Amphastar Pharma (AMPH) had an operating margin of 28.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Amphastar Pharma's net profit margin?
Amphastar Pharma (AMPH) had a net profit margin of 21.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Amphastar Pharma's return on equity (ROE)?
Amphastar Pharma (AMPH) has a return on equity of 21.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Amphastar Pharma's free cash flow?
Amphastar Pharma (AMPH) generated $172.3M in free cash flow during fiscal year 2024. This represents a 18.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Amphastar Pharma's operating cash flow?
Amphastar Pharma (AMPH) generated $213.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Amphastar Pharma's total assets?
Amphastar Pharma (AMPH) had $1.6B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Amphastar Pharma's capital expenditures?
Amphastar Pharma (AMPH) invested $41.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Amphastar Pharma spend on research and development?
Amphastar Pharma (AMPH) invested $73.9M in research and development during fiscal year 2024.
Does Amphastar Pharma buy back shares?
Yes, Amphastar Pharma (AMPH) spent $85.5M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Amphastar Pharma have outstanding?
Amphastar Pharma (AMPH) had 48M shares outstanding as of fiscal year 2024.
What is Amphastar Pharma's current ratio?
Amphastar Pharma (AMPH) had a current ratio of 3.07 as of fiscal year 2024, which is generally considered healthy.
What is Amphastar Pharma's debt-to-equity ratio?
Amphastar Pharma (AMPH) had a debt-to-equity ratio of 0.84 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Amphastar Pharma's return on assets (ROA)?
Amphastar Pharma (AMPH) had a return on assets of 10.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Amphastar Pharma's Altman Z-Score?
Amphastar Pharma (AMPH) has an Altman Z-Score of 2.60, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Amphastar Pharma's Piotroski F-Score?
Amphastar Pharma (AMPH) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Amphastar Pharma's earnings high quality?
Amphastar Pharma (AMPH) has an earnings quality ratio of 1.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Amphastar Pharma cover its interest payments?
Amphastar Pharma (AMPH) has an interest coverage ratio of 6.8x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Amphastar Pharma?
Amphastar Pharma (AMPH) scores 89 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.